Turning to neuroscience, where in the third quarter, JUVMO was approved by the FDA for Parkinson's disease. Dopamine agonists have long been used to help manage symptoms and reduce reliance on oral levatopa escalation. However, currently available agents primarily target D2-D3 receptors, and their use has been limited by adverse events. As a selective D1-D5 receptor agonist, JuveMO demonstrated strong motor control and a favorable tolerability profile ? with low rates of dyskinesia, sedation, and impulse control disorder, which have historically impacted the use of dopamine agonists. Additionally, long-term data continue to support a reduced reliance on oral levadopa when taking JUVMO. After more than a year and a half on JUVMO, 93% of patients had not increased their Levadopa dose, and 94% of patients with early Parkinson's disease had not started oral levitopa. Physicians and patients now have a treatment option that targets dopamine pathways differently and may reduce the difficult trade-offs associated with D2D3 agonists. In psychiatry, the amraclidine dose escalation study has completed. The 150 milligram dose will be utilized ? in the monotherapy and adjunctive phase two studies in schizophrenia, with enrollment expected to begin by the end of this year. This new dose is five times the highest dose evaluated in the previous two pivotal trials. The 150 milligram dose was well tolerated and no new safety signals were identified. We look forward to advancing this higher dose for schizophrenia, which may result in greater efficacy compared to prior studies. Doses have also been selected for the psychosis program, where phase two studies in Alzheimer's and Parkinson's disease are expected to begin early next year. Moving to our psychedelic acid, Braticillosin, a phase three trial evaluating a single course acute treatment in major depressive disorder is expected to begin later this year. We also remain on track for additional phase two data in monotherapy MDD by year end, which will help inform the phase two study evaluating repeat dosing for chronic use. This MDD study, as well as phase two proof of concepts in post-traumatic stress, generalized anxiety, and obsessive compulsive disorders, are expected to begin in 2027. In migraine, positive top-line results were announced from the Phase III LUNA study, which evaluated CULYPTA for the preventive treatment of menstrual migraine. No medicines are currently approved for menstrual migraine attacks, which are considered more difficult to treat, more disabling, tend to last longer, and have a higher tendency to recur. This underscores the need for effective treatment strategies for this distinct disorder. ? In the Luna trial, CULYPTA demonstrated meaningful and statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo. A regulatory application will be submitted soon in Europe. Additionally, phase three results for Ubrelvi in menstrual migraine prevention are expected near the end of the year, which will potentially support a submission in the US in early 2027. Moving to hematologic oncology. Positive top-line results were announced from the Phase III Cerveno trial evaluating attentamig monotherapy versus standard of care in heavily pretreated triple class exposed multiple myeloma patients. AttentaMIG delivered statistically significant and clinically meaningful improvements in progression free survival and overall response rates with a manageable safety profile, supporting its potential to become an important new treatment option for multiple myeloma. BCMA directed bi specifics and CAR T therapies have transformed multiple myeloma treatment. However, their adoption, particularly among community based centers, remains limited by adverse events such as CRS, neurotoxicity, and serious infections, as well as the need for specialized monitoring. With a differentiated safety profile, simplified onboarding, and a more convenient once-monthly dosing schedule after a single step-up dose, AtentamIG has the potential to streamline treatment and expand access across settings, including community-based clinics. A regulatory application was recently submitted to the FDA with an approval decision anticipated next year. Beyond the Chervino program, two new Phase III trials were recently initiated for a Tentamig, one in combination with pomolidomide in secondline plus multiple myeloma, and another as a monotherapy in patients with newly diagnosed light chain amyloidoses. ? And at the upcoming ASH meeting, early results from a phase two study evaluating atentameg plus derotumumab in frail, transplant ineligible frontline multiple myeloma will be presented, with a third phase three study potentially starting next year. Continuing with other HEMONT programs, positive top line results were announced from the Phase III EPCOR DLBCL II trial evaluating EPKI in combination with RCOP in frontline DLBCL. The study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to RCOP alone. EPKINLY plus RCOP showed an overwhelming treatment benefit at this interim analysis, reducing the risk of disease progression or death by 51% in a broad population covering patients with international prognostic index scores between two and five. Importantly, this is the first phase three study with a bi-specific antibody combination to demonstrate a progression-free survival benefit in frontline. Supporting the potential for Fkinley plus RCOP to become a new standard of care in this setting, Regulatory submissions are anticipated early next year. Turning to solid tumors, at the World Conference on Lung Cancer, results from a phase one study evaluating our PD1 VEGF bi-specific antibody, ABB 1480, in frontline non-small cell lung cancer were presented. These early data were particularly encouraging given the activity observed in PDL1 negative patients, a group which has traditionally been more difficult to treat. A phase three study was recently initiated to evaluate 1480 in combination with chemotherapy in frontline squamous and non-squamous small cell lung cancer. We also intend to move quickly to evaluate 1480 in combination with our ADCs across several tumor types. Two phase two studies evaluating 1480 plus TMABA were recently initiated, one one in non-small cell lung cancer and another in colorectal cancer. And a phase two combination study with ABB 706, our CES 6ADC, will begin next year in small cell lung cancer.
Passages & reports (30) 19:25 Turning to neuroscience, where in the third quarter, JUVMO was approved by the FDA for Par… Report 19:45 receptors, and their use has been limited by adverse events. As a selective D1-D5 receptor… Report 20:00 with Report 20:00 low rates of dyskinesia, sedation, and impulse control disorder, which have historically i… Report 20:20 93% of patients had not increased their Levadopa dose, and 94% of patients with early Park… Report 20:40 trade-offs associated with D2D3 agonists. In psychiatry, the amraclidine dose escalation s… Report 20:55 in Report 20:55 the monotherapy and adjunctive phase two studies in schizophrenia, with enrollment expecte… Report 21:15 new safety signals were identified. We look forward to advancing this higher dose for schi… Report 21:35 early next year. Moving to our psychedelic acid, Braticillosin, a phase three trial evalua… Report 21:55 MDD by year end, which will help inform the phase two study evaluating repeat dosing for c… Report 22:15 expected to begin in 2027. In migraine, positive top-line results were announced from the … Report 22:34 migraine attacks, which are considered more difficult to treat, more disabling, tend to la… Report 22:50 In Report 22:51 the Luna trial, CULYPTA demonstrated meaningful and statistically significant reductions i… Report 23:11 phase three results for Ubrelvi in menstrual migraine prevention are expected near the end… Report 23:30 Phase III Cerveno trial evaluating attentamig monotherapy versus standard of care in heavi… Report 23:50 overall response rates with a manageable safety profile, supporting its potential to becom… Report 24:09 particularly among community based centers, remains limited by adverse events such as CRS,… Report 24:29 once-monthly dosing schedule after a single step-up dose, AtentamIG has the potential to s… Report 24:49 year. Beyond the Chervino program, two new Phase III trials were recently initiated for a … Report 25:09 And Report 25:09 at the upcoming ASH meeting, early results from a phase two study evaluating atentameg plu… Report 25:29 with other HEMONT programs, positive top line results were announced from the Phase III EP… Report 25:49 progression-free survival compared to RCOP alone. EPKINLY plus RCOP showed an overwhelming… Report 26:09 and five. Importantly, this is the first phase three study with a bi-specific antibody com… Report 26:29 setting, Regulatory submissions are anticipated early next year. Turning to solid tumors, … Report 26:49 in frontline non-small cell lung cancer were presented. These early data were particularly… Report 27:09 combination with chemotherapy in frontline squamous and non-squamous small cell lung cance… Report 27:28 initiated, one one in non-small cell lung cancer and another in colorectal cancer. And a p… Report